MedPath

To compare effectiveness of platelet rich plasma (blood component) and tranexamic acid with dermaroller in melasma

Not Applicable
Completed
Conditions
Health Condition 1: - Health Condition 2: L811- Chloasma
Registration Number
CTRI/2021/07/034631
Lead Sponsor
Department of Dermatology Government Medical College and Hospital Sector B Chandigarh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

1.Patients with clinical diagnosis of melasma (bilaterally symmetrical distribution).

2.Patients above the age of 18 years and below the age of 50 years.

Exclusion Criteria

1.Patients with a history of bleeding disorders

2.Patients with hemoglobin level < 10 g/dl.

3.Patients with local inflammatory skin disorders at the site of the procedure.

4.Patients with use of systemic corticosteroids within 2 weeks or corticosteroid injection application within 1 month at the site of procedure.

5.Patient with known hypersensitivity to platelet rich plasma or any other form of blood components and to tranexamic acid.

6.Patients with any other facial dermatoses.

7.Patients on anticoagulants, oral contraceptive pills

8.Patients using photosensitizing an use of other depigmenting oral or topical agents.

9.Pregnancy and lactation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess the comparative efficacy of platelet rich plasma therapy and tranexamic acid with microneedling in melasma.Timepoint: 0,3,6,9 weeks
Secondary Outcome Measures
NameTimeMethod
To assess adverse effects of platelet rich plasma and tranexamic acid with microneedling in melasma.Timepoint: 0,3,6,9 weeks
© Copyright 2025. All Rights Reserved by MedPath